The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Adverum Biotechnologies, Inc. Common Stock 00773U108   3,635,950 5,068,233 SH   OTR   0 5,068,233 0
Aligos Therapeutics, Inc. Common Stock 01626L105   2,028,013 2,320,381 SH   OTR   0 2,320,381 0
CRISPR Therapeutics AG Common Shares H17182108   22,549,778 498,558 SH   OTR   0 498,558 0
CymaBay Therapeutics, Inc. Common Stock 23257D103   4,741,526 543,753 SH   OTR   0 543,753 0
Gritstone Oncology, Inc. Common Stock 39868T105   9,899,997 3,561,150 SH   OTR   0 3,561,150 0
Minerva Surgical Inc. Common Stock 60343F106   367,377 1,673,700 SH   OTR   0 1,673,700 0
Passage Bio, Inc. Common Stock 702712100   4,749,971 4,959,769 SH   OTR   0 4,959,769 0